Neuralink: revision 1 to 5 — Future Human Wiki

Revision 1

Revision 5

horizon: "late 2020s"

categories: ["organizations", "cybernetics"]

tags: ["bci", "neurotechnology", "implants", "elon musk", "clinical trials", "paralysis"]

summary: "American neurotechnology company founded in 2016 developing a wireless implanted brain–computer interface with flexible electrode threads inserted by a surgical robot."

summary: "American neurotechnology company founded in 2016 developing a wireless implanted brain-computer interface with flexible electrode threads inserted by a surgical robot."

updated: "2026-07-27"

updated: "2026-11-01"

issues: ["Series E size and valuation are attributed to the company with no citation.", "Blindsight and CONVOY paragraphs rest on company statements not cited as footnotes."]

issues: ["Participant counts after January 2026 come only from secondary trackers; add once Neuralink or a registry confirms.", "Unconfirmed whether the next-generation robot has been used in a trial surgery; add once Neuralink says so."]

---

```infobox

{ "label": "Headquarters", "value": "Fremont, California" },

{ "label": "Co-founder", "value": "Elon Musk" },

{ "label": "Products", "value": "N1 implant, R1 surgical robot" },

{ "label": "Programmes", "value": "Telepathy, speech (VOICE), Blindsight" },

{ "label": "First human implant", "value": "January 2024" },

{ "label": "Regulatory status", "value": "Investigational (FDA IDE)" },

{ "label": "Trial countries", "value": "US, Canada, UK, UAE" },

{ "label": "Focus", "value": "Motor decoding, visual prosthesis" }

{ "label": "Regulatory status", "value": "Investigational, not approved" },

{ "label": "Focus", "value": "Motor and speech decoding, visual prosthesis" }

]

}

```

**Neuralink** is a privately held American company developing an implanted

[[brain-computer-interface]] consisting of a coin-sized wireless processor and a set of thin

polymer threads carrying electrodes, inserted into cortex by a purpose-built surgical robot. It was

founded in 2016 by a group including Elon Musk, who has been its public face and principal funder.

founded in 2016 by a group including [Elon Musk](https://aiwiki.ai/wiki/elon_musk), who has been its public face and principal funder.

The company began implanting the device in humans in January 2024 under an FDA investigational

device exemption.

device exemption, and in January 2026 it said 21 people were enrolled in its trials

worldwide.[^twoyears2026] As of October 2026 its devices remain investigational and unapproved by

any regulator.[^nltelepathy]

Neuralink's technical contribution is largely in engineering and surgery rather than neuroscience:

Neuralink's technical contribution lies largely in engineering and surgery rather than

flexible electrode threads that move with the brain, automated insertion, high channel counts in a

neuroscience: flexible electrode threads that move with the brain, automated insertion, high

sealed wireless package, and a hermetic implant with no percutaneous connector. Its scientific

channel counts in a sealed wireless package, and a hermetic implant with no percutaneous connector.

results to date have been communicated mainly through livestreams and company blog posts rather

Its scientific results to date have been communicated mainly through livestreams, company blog

than peer-reviewed publication, which is the most common criticism levelled at it by academic BCI

posts and social media rather than peer-reviewed publication, the criticism academic BCI

researchers.

researchers most often level at it.

## Technology

The N1 implant houses a battery, wireless radio, and signal-processing electronics in a package

that sits in a recess milled into the skull, flush with the surrounding bone. From it extend 64

polymer threads bearing 16 electrodes each — 1,024 channels in total — each thread narrower than a

polymer threads bearing 16 electrodes each, 1,024 electrodes in total.[^nlink2024a] Each thread is narrower than

human hair and far more compliant than the rigid silicon shanks of a [[utah-array]]. The design

a human hair and far more compliant than the rigid silicon shanks of a [[utah-array]]. The design

intent is to reduce the micromotion-driven tissue damage that drives glial encapsulation and signal

is meant to reduce the micromotion-driven tissue damage that causes glial encapsulation and signal

loss in stiff arrays.

Because the threads are too floppy to insert by hand, the R1 robot uses a needle and optical

guidance to place each one individually, steering around surface vasculature. The company described

the architecture in a 2019 white paper based on rodent work.[^musk2019] Recording, spike detection,

the architecture in a 2019 white paper based on rodent work.[^musk2019] The implant processes the

and compression happen on the implant; decoded output is sent over Bluetooth to an external device.

electrode signals and sends them wirelessly to a Neuralink application on an external device such as

Users control a cursor by attempting or imagining movement, with the mapping learned by a decoder

a computer, which runs the decoder; the battery is recharged inductively through the scalp.[^nlink2024a]

that is periodically recalibrated — the same basic paradigm of [[neural-decoding]] established in

The company says an hour of charging gives 4-8 hours of use, depending on the implant

version.[^nltelepathy] Users control a cursor by attempting or imagining movement, and a periodically recalibrated

decoder learns the mapping. This is the same basic paradigm of [[neural-decoding]] established in

academic laboratories two decades earlier.[^hochberg2006][^gilja2012]

The device is read-only in its current form. It records but does not stimulate, which places it in

The hardware is changing. In January 2026 the company said it was moving from roughly 1,000 to

a different category from the implanted neurotechnologies already in routine clinical use, such as

3,000 electrodes per implant, testing mechanical features to keep threads anchored, and

investigating inserting threads through the dura mater rather than removing it.[^twoyears2026] In

June 2026 it reported its first procedure in which the threads went straight through an intact

dura into cortex.[^nltransdural2026]

The robot is being redesigned as well. In a June 2025 company presentation a Neuralink engineer said the R1

that implanted the first seven participants needed 17 seconds per thread at best, and presented a

next-generation robot that he said inserts each thread in 1.5 seconds, can place threads more than

50 mm below the brain surface, and is compatible with more than 99% of the

population.[^nlsummer2025] In a recruiting talk published in December 2025, co-founder DJ Seo said

the robot in clinical use had implanted 13 people, placing threads about 4 mm deep.[^nlfall2025] An

April 2026 company video showed the new design's eight cameras and an optical coherence tomography

sensor that sees beneath the tissue surface; its engineers said it moves in five axes so it can

reach more regions of the brain, and that it was "not in its final form".[^nlrobot2026] All of these

figures are Neuralink's own.

As used in its trials so far, the device records but does not stimulate, which puts it in a

different category from the implanted neurotechnologies already in routine clinical use, such as

the [[cochlear-implant]] and [[deep-brain-stimulation]], which write signals in rather than

reading them out. Adding a stimulation channel is a stated goal and is required for the visual

reading them out. Stimulation is required for the visual programme, but the safety profile of

programme, but the safety profile of chronic cortical stimulation is less well characterized than

chronic cortical stimulation is less well characterized than that of chronic recording.

that of chronic recording.

```timeline

[

  { "year": "2019", "title": "Threads and robot unveiled", "text": "A launch event and accompanying white paper describe polymer electrode threads, robotic insertion, and rodent recordings." },

  { "year": "2019", "title": "Threads and robot unveiled", "text": "A launch event and accompanying white paper describe polymer electrode threads, robotic insertion, and rodent recordings." },

  { "year": "2020", "title": "Pig demonstration", "text": "A livestream shows live neural recordings from an implanted pig, demonstrating a sealed wireless device rather than any new decoding capability." },

  { "year": "2020", "title": "Pig demonstration", "text": "A livestream shows live neural recordings from an implanted pig, demonstrating a sealed wireless device rather than any new decoding capability." },

  { "year": "2021", "title": "Macaque cursor control", "text": "A monkey plays a cursor-based video game using the implant, replicating a capability shown in primate laboratories years earlier." },

  { "year": "2021", "title": "Macaque cursor control", "text": "A monkey plays a cursor-based video game using the implant, replicating a capability shown in primate laboratories years earlier." },

  { "year": "2023", "title": "Human trial cleared", "text": "The FDA grants an investigational device exemption; the PRIME study opens recruitment for people with quadriplegia." },

  { "year": "2023", "title": "Human trial cleared", "text": "The FDA grants an investigational device exemption in May; the PRIME study opens recruitment in September for people with quadriplegia." },

  { "year": "2024", "title": "First human implants", "text": "The first participant receives the device in January; the company later discloses that many threads retracted from the cortex, and modifies its technique for subsequent surgeries." },

  { "year": "2024", "title": "First human implants", "text": "The first participant receives the device in January; the company later discloses that many threads retracted from the cortex. Blindsight receives an FDA breakthrough device designation; CAN-PRIME and the CONVOY robotic-arm study open." },

  { "year": "2024–2026", "title": "International expansion", "text": "Regulators in Canada, the United Kingdom, and the United Arab Emirates permit studies; the company reports additional participants and a robotic-arm extension study." }

  { "year": "2025", "title": "Speech and expansion", "text": "Speech restoration receives a breakthrough device designation; studies open in the United Arab Emirates and Great Britain; the VOICE speech study starts in October. In June the company shows a faster next-generation surgical robot." },

  { "year": "2026", "title": "Speech data and Blindsight wait", "text": "The company reports 21 enrolled participants in January and early speech results at a conference in October; Musk says Blindsight awaits regulatory approval." }

]

```

## Human trials

The PRIME study enrols adults with quadriplegia from cervical spinal cord injury or amyotrophic

### Device control: PRIME and Telepathy

lateral sclerosis. The first participant, Noland Arbaugh, received an implant in January 2024 and

within weeks was using it to move a cursor, play chess and video games, and operate a computer for

long stretches daily.

The PRIME study (Precise Robotically Implanted Brain-Computer Interface) runs under an FDA

investigational device exemption granted in May 2023 and enrols adults with quadriplegia from

cervical spinal cord injury or amyotrophic lateral sclerosis.[^nlink2023] The first participant,

Noland Arbaugh, received an implant at Barrow Neurological Institute in Phoenix in January

2024.[^nlink2024a] Within weeks he was using it to move a cursor, play chess and video games, and

operate a computer for long stretches daily; the company reported research sessions of up to eight

hours on weekdays.[^nlink2024]

In the weeks after that surgery a substantial fraction of the threads retracted from the cortex,

reducing the number of channels recording usable signal. Neuralink disclosed this in a blog post

several months later and reported recovering performance through changes to signal processing and

decoding rather than reimplantation.[^nlink2024] For the second participant the company said it

altered its technique, sculpting the skull surface to reduce the gap under the implant and

reduced brain motion during surgery and narrowed the gap between the implant and the brain surface,

inserting threads deeper. Thread retraction is a specific instance of the general problem that

and it reported no thread retraction in that participant.[^nlink2024b] By January 2026 it said 18 of

afflicts every penetrating array: the brain moves, pulses, and reacts to foreign material.

the 20 participants implanted after these changes showed higher signal quality, while performance

still varied with anatomy and with disease stage.[^twoyears2026] Thread retraction is one

instance of a general problem for every penetrating array, which is that the brain moves, pulses,

and reacts to foreign material.

A companion study, CONVOY, extends control from a cursor to an assistive robotic arm, moving the

Neuralink calls the device-control application Telepathy. On the company's own description it is a

device from computer access toward the broader ambitions of [[neuroprosthetics]]. The company has

mind-controlled mouse: participants move a cursor and issue left, right and middle clicks by

also said it intends to pursue speech decoding, a capability demonstrated by academic groups using

attempting or imagining hand movements, mainly on a supplied MacBook, and keeping control may take

surface and penetrating arrays and covered under [[speech-neuroprosthesis]]. A separate

up to a few hours of calibration a week. Keyboard, game-console, wheelchair and robotic-arm control

programme, Blindsight, aims to restore a crude visual percept by stimulating visual cortex directly;

are experimental features not available to every participant.[^nltelepathy] The company reports

it received an FDA breakthrough device designation in 2024 but had no published human results as of

that several participants have reached and sometimes exceeded the 8-10 bits per second it gives for able-bodied mouse

early 2026. Cortical visual prostheses have a long and largely disappointing history, and the

use, that a "ten finger keyboard for the mind" decoded from imagined finger movements has reached 40 words per

resolution limits that constrained earlier efforts — described under [[retinal-implant]] — apply

minute, and that its trials have had no serious device-related adverse events.[^twoyears2026] All

with equal force here.

three figures are self-reported.

The same protocol now runs in other countries: CAN-PRIME at University Health Network in Toronto

from November 2024,[^canprime2024][^ctcanprime] UAE-PRIME at Cleveland Clinic Abu Dhabi from May

2025,[^ctuae] and GB-PRIME at University College London Hospitals and Newcastle from July

2025.[^gbprime2025] A companion study, CONVOY, opened in November 2024 to let PRIME participants

control an investigational assistive robotic arm,[^ctconvoy] moving the device from computer access

toward the broader ambitions of [[neuroprosthetics]]; in January 2026 the company described a

participant using a robotic arm to feed himself.[^twoyears2026]

### Speech restoration: VOICE

The FDA granted Neuralink a breakthrough device designation for speech restoration in May

2025.[^nlspeech2025] Its speech study, VOICE, began in October 2025 at UT Southwestern Medical Center

under principal investigator Nader Pouratian, with an estimated enrolment of six adults with severe

speech impairment and impaired arm function.[^ctvoice] Instead of the hand area used for Telepathy,

the threads go into speech motor cortex, and a decoder turns attempted or imagined speech into text

or into synthesized speech in a re-creation of the participant's own former voice.[^nlspeechpage]

This is the paradigm demonstrated earlier by academic groups and covered under

[[speech-neuroprosthesis]].

The company says its median speech participant decodes about 50 words per minute, against roughly

150 for natural conversation.[^nlspeechpage] On 28 October 2026 it reported that one participant

with ALS reached 75 words per minute at a 5.8% word error rate, on a 125,000-word vocabulary, in

the first week of use. Those figures were presented as an abstract at the annual Northeast ALS

Consortium meeting rather than in a full peer-reviewed paper.[^nlneals2026] A day later Neuralink

publicized a 72-hour engineering visit to a VOICE participant that produced prototypes including

automatic detection of when the user is trying to speak, an integration of the company's existing

speech app, Bloom, with iPhone calls, and a feature that starts a Grok computer-use agent when the user

thinks of saying "Hey Neuralink".[^nlhack2026]

### Blindsight

Blindsight is Neuralink's visual prosthesis: an implant meant to produce visual percepts by

stimulating visual cortex directly, bypassing the eyes and optic nerve. The FDA gave it a

breakthrough device designation in September 2024,[^nlblind2024] a status that speeds contact with

the agency but is not a finding of safety or effectiveness. Musk wrote at the time that it would

let people who had lost both eyes and optic nerves see and, "provided the visual cortex is intact",

people blind from birth, while warning that vision would at first be low resolution, "like Atari

graphics". A vision scientist interviewed by IEEE Spectrum that month pointed out that no preclinical

evaluation of the device had been published.[^uyeno2024]

As of October 2026 no Blindsight study had been registered on ClinicalTrials.gov or announced by

the company. Neuralink's

visual-prosthesis page asked people to join its patient registry to be told when U.S. trials

begin,[^nlvisual] and on 30 October 2026 Musk wrote that the device was "ready from an engineering

standpoint" and "Just waiting on regulatory approval".[^musk2026b] The same post said it would let

"even those who are completely blind or have never seen" see, dropping the earlier proviso. By

that proviso the approach depends on a working visual cortex, so it cannot help blindness caused

by damage there. Cortical prostheses have also been tested mainly in people who lost their sight

later in life, and whether one can usefully restore vision to someone born blind, who has never

used the visual cortex as a sighted person does, remains an open question.[^smutny2026] Experts in 2024

expected even the best cortical implant buildable with current technology to produce nothing like

normal vision, at most an aid alongside a cane or guide dog, though one added that it might still

transform blind people's lives.[^uyeno2024] Earlier attempts are

covered under [[cortical-visual-prosthesis]], and the resolution limits that constrained them,

described under [[retinal-implant]], apply with equal force here.

> [!caution] Company reporting, not trial reporting

> Participant counts, performance figures, and adverse-event descriptions for Neuralink's studies

> have come predominantly from company statements and social media. As of 2026 there is no

> have come predominantly from company statements, livestreams and social media. In October 2025

> peer-reviewed clinical publication from the PRIME study, which makes independent assessment of

> Bloomberg reported that a paper on the first three PRIME participants had been submitted to the

> durability, complication rates, and decoder performance impossible.

> *New England Journal of Medicine*.[^debrief2025] As of October 2026 no peer-reviewed clinical

> report from any Neuralink trial has been published, and the speech results exist only as a

> conference abstract, so durability, complication rates, and decoder performance cannot yet be

> assessed independently.

## Funding and structure

Neuralink is funded by venture capital and by Musk personally. It raised a Series E in 2025 that

Neuralink is funded by venture capital and by Musk personally. It announced a $280 million Series D

the company said totalled several hundred million dollars at a valuation in the billions, a figure

led by Founders Fund in August 2023[^nlseriesd] and a $650 million Series E in June 2025, with

far above what any BCI company has justified on revenue, since none has an approved product. The

investors including ARK Invest, Founders Fund, G42, Sequoia Capital and Thrive Capital.[^nlseriese]

capital advantage is real: implant development, robot engineering, animal work, and multi-country

The company did not publish a valuation; Semafor reported that the Series E valued it at about

regulatory submissions are expensive in a way academic consortia such as BrainGate cannot match.

$9 billion before the new money.[^zeff2025] That figure does not rest on product revenue, since

Neuralink has no approved product. The capital advantage is real. Implant development, robot

engineering, animal work, and multi-country regulatory submissions cost more than academic

consortia such as BrainGate can spend. At the end of 2025 Musk said the company would start

"high-volume production" of its devices and move to an automated surgical procedure in

2026,[^reuters2025] a forecast that depends on regulators as much as on engineering.

The founding team has largely dispersed. Several co-founders left within the first few years, and

one went on to co-found Precision Neuroscience, which pursues a thin-film surface approach closer

to [[ecog-interfaces]] than to penetrating threads. Competitors now span the invasiveness spectrum,

to [[ecog-interfaces]] than to penetrating threads. In December 2025 the company hired David

including [[synchron]] with its endovascular [[stentrode]], Paradromics with a high-channel

McMullen, who had previously worked at DARPA, the NIH and the FDA, to lead its medical

penetrating array, and Blackrock Neurotech.

affairs.[^nlmcmullen] Competitors now span the invasiveness spectrum, including [[synchron]] with

its endovascular [[stentrode]], Paradromics with a high-channel penetrating array, and Blackrock

Neurotech.

## Reception

Assessments divide along a consistent line. Engineers credit the company with solving practical

problems the field had left unsolved: a fully implanted wireless device with no skull-mounted

pedestal, an insertion robot that makes hundreds of precise placements, and a manufacturing process

for polymer electrode arrays. Those are the bottlenecks between a laboratory demonstration and a

for polymer electrode arrays. Those problems stand between a laboratory demonstration and a

product.

Neuroscientists are more sceptical of the framing. The cursor control demonstrated in 2024 was

qualitatively similar to results published from academic implants more than a decade earlier, and

the product name "Telepathy" describes typing with a decoder, not thought transmission — an

the product name "Telepathy" describes controlling a computer with a decoder rather than thought

overstatement of the kind examined under [[brain-to-brain-interface]]. Claims that the device will

transmission, an overstatement of the kind examined under [[brain-to-brain-interface]]. In October

one day enable symbiosis with artificial intelligence, discussed as [[human-ai-merger]], are

2026 Musk described Telepathy as enabling "high-speed communication with computers or humans

untested and rest on a bandwidth argument that the low-dimensional structure of cortical activity

simply by thinking" and predicted that its output bandwidth "will vastly exceed the fastest human

does not obviously support.

speech or typing in a few years".[^musk2026a] Any communication with other people runs through a

computer, speech is handled by the separate VOICE study, and the highest speech rate the company

has reported is about half the conversational rate it cites itself.[^nlneals2026][^nlspeechpage] Claims

that the device will one day enable symbiosis with artificial intelligence, discussed as

[[human-ai-merger]], are untested and rest on a bandwidth argument that the low-dimensional

structure of cortical activity does not obviously support.

The company has also faced sustained criticism over animal research. Reuters reported in 2022 that

federal investigators were examining animal-welfare practices following internal complaints, and a

federal investigators were examining animal-welfare practices following internal

separate inquiry concerned the transport of hardware removed from primate brains.[^reuters2022] An

complaints.[^reuters2022] In 2023 the Department of Transportation opened an inquiry into the

advocacy organization filed complaints over primate experiments conducted at a university partner.

packaging and transport of implants removed from monkeys' brains, after the Physicians Committee for

Neuralink has denied wrongdoing and published its own account of its animal-care programme.

Responsible Medicine, an advocacy group, obtained records of primate experiments Neuralink had run

with the University of California, Davis.[^reuters2023] Neuralink has denied wrongdoing and

published its own account of its animal-care programme.

A third strand of criticism concerns data. A device that streams cortical activity to a phone

creates a record of neural signals held by a private company, raising the questions taken up under

creates a record of neural signals held by a private company, which raises the questions taken up

[[mental-privacy]] — not because a cursor decoder reads thoughts, but because the underlying

under [[mental-privacy]]. A cursor decoder does not read thoughts, but the underlying recordings

recordings support inferences the user never intended to make available.

support inferences the user never intended to make available.

## Outlook

The questions that will determine whether Neuralink matters are unglamorous. Do threads stay put

The questions that will determine whether Neuralink matters are practical ones: whether threads

over five years? What fraction of participants develop infection or require explant? Can a decoder

stay put over five years, what fraction of participants develop infection or require explant,

run for weeks without a technician? Does the device work in a home, unsupervised, on a bad day? The

whether a decoder can run for weeks without a technician, and whether the device works in a home,

company's willingness to run multi-country studies suggests a push toward a pivotal trial, but no

unsupervised, on a bad day. Every trial Neuralink has registered so far is described as a

implanted BCI from any developer has yet been approved for routine clinical use, and the regulatory

feasibility study.[^ctvoice][^ctuae] Elsewhere, China's medical-products regulator approved

path for a permanent cortical implant in a non-fatal condition has no precedent to follow.

Neuracle's NEO in March 2026, an implant placed outside the dura that drives a pneumatic glove,

in what was widely reported as the first commercial approval of an implanted

BCI.[^cgtn2026] Neuralink's penetrating threads have no such approval, and the company has not announced the

larger pivotal trial a marketing application would normally need.

A separate question is what happens if the company stops. Implanted devices create obligations that

outlast product lines, an issue that the emerging [[neurorights]] frameworks have begun to name but

outlast product lines, an issue the emerging [[neurorights]] frameworks have begun to name but have

not yet resolved.

## See also

- [[brain-computer-interface]]

- [[speech-neuroprosthesis]]

- [[cortical-visual-prosthesis]]

- [[stentrode]]

- [[utah-array]]

- [[speech-neuroprosthesis]]

- [[neural-decoding]]

- [[neuroprosthetics]]

- [[mental-privacy]]

- [[synchron]]

[^gilja2012]: `paper` Gilja, V. et al. "A high-performance neural prosthesis enabled by control algorithm design." *Nature Neuroscience*, 2012.

[^gilja2012]: `paper` Gilja, V. et al. "A high-performance neural prosthesis enabled by control algorithm design." *Nature Neuroscience*, 2012.

[^nlink2024]: `statement` Neuralink. "PRIME Study Progress Update." Company blog post, 2024. {The sole source for the thread-retraction episode and the recovery from it; none of it has been peer-reviewed or published as a clinical report.}

[^nlink2023]: `statement` Neuralink. "Neuralink's First-in-Human Clinical Trial is Open for Recruitment." Company blog post, 19 September 2023.

[^nlink2024a]: `statement` Neuralink. "PRIME Study Progress Update." Company blog post, 12 April 2024. {Describes the N1 implant, R1 robot and first surgery; it predates the company's disclosure of thread retraction.}

[^nlink2024]: `statement` Neuralink. "PRIME Study Progress Update — User Experience." Company blog post, 8 May 2024. {The sole source for the thread-retraction episode and the recovery from it; none of it has been peer-reviewed or published as a clinical report.}

[^nlink2024b]: `statement` Neuralink. "PRIME Study Progress Update — Second Participant." Company blog post, 21 August 2024.

[^canprime2024]: `statement` Neuralink. "CAN-PRIME Study Launch." Company blog post, 20 November 2024.

[^ctcanprime]: `trial` ClinicalTrials.gov NCT06700304. "CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices." Sponsor: Neuralink; start date 20 November 2024; site University Health Network, Toronto. https://clinicaltrials.gov/study/NCT06700304

[^ctconvoy]: `trial` ClinicalTrials.gov NCT06710626. "Control of Assistive Devices Via Brain-Computer Interface Technology." Official title includes "CONVOY". Sponsor: Neuralink; start date 25 November 2024.

[^ctuae]: `trial` ClinicalTrials.gov NCT06992596. "UAE-PRIME: A Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices." Sponsor: Neuralink; start date 9 May 2025.

[^gbprime2025]: `statement` Neuralink. "GB-PRIME Study Launch." Company blog post, 31 July 2025.

[^nlblind2024]: `statement` Neuralink. "Neuralink Receives Breakthrough Device Designation for Blindsight." Company blog post, 17 September 2024.

[^nlspeech2025]: `statement` Neuralink. "Neuralink Receives Breakthrough Device Designation for Speech." Company blog post, 1 May 2025.

[^ctvoice]: `trial` ClinicalTrials.gov NCT07224256. "VOICE: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for Communication Restoration." Sponsor: Neuralink; start date 3 October 2025.

[^nlspeechpage]: `statement` Neuralink. "Speech Restoration." Clinical trials web page, neuralink.com/trials/speech-restoration, accessed 30 October 2026. {Recruitment page; the 50 words-per-minute median is the company's figure with no stated participant count or method.}

[^nltelepathy]: `statement` Neuralink. "Telepathy." Clinical trials web page, neuralink.com/trials/device-control, accessed 30 October 2026.

[^nlvisual]: `statement` Neuralink. "Visual Prosthesis." Clinical trials web page, neuralink.com/trials/visual-prosthesis, accessed 30 October 2026.

[^twoyears2026]: `statement` Neuralink. "Two Years of Telepathy." Company blog post, 28 January 2026. {Participant counts, signal-quality trends and the adverse-event record are all self-reported, with no accompanying data release.}

[^nltransdural2026]: `statement` Neuralink. "Our First Transdural Procedure." Company video, 30 June 2026.

[^nlsummer2025]: `statement` Neuralink. "Neuralink Update, Summer 2025." Company presentation video, premiered 27 June 2025. https://www.youtube.com/watch?v=FASMejN_5gs {The robot figures come from a segment presented by the company's robot mechanical lead, which gives no test data behind them.}

[^nlfall2025]: `statement` Neuralink. "Neuralink Overview, Fall 2025." Company video of a recruiting presentation by DJ Seo, published 3 December 2025. https://www.youtube.com/watch?v=QJdgHXyJh7M

[^nlrobot2026]: `statement` Neuralink. "Automating Neurosurgery with Robotics." Company video, 29 April 2026, also posted on X. https://www.youtube.com/watch?v=KO53gwuqZUQ (X: https://x.com/neuralink/status/2049519486688972991)

[^nlneals2026]: `statement` Neuralink. Post on X reporting early speech restoration data, 28 October 2026. {Summarizes an abstract presented at the 2026 Northeast ALS Consortium meeting and printed in a Muscle and Nerve proceedings supplement, not a full peer-reviewed paper.}

[^nlhack2026]: `statement` Neuralink. "A 72-Hour Engineering Sprint for Translating Thought to Speech." Company blog post and X thread, 29 October 2026.

[^musk2026a]: `statement` Musk, E. Post on X describing Telepathy, 30 October 2026.

[^musk2026b]: `statement` Musk, E. Post on X describing Blindsight, 30 October 2026.

[^uyeno2024]: `news` Uyeno, G. "Neuralink's Blindsight Implant Won't Deliver Natural Sight." *IEEE Spectrum*, 27 September 2024 (print title "Neuralink's Blindsight Device Is Likely to Disappoint", December 2024). https://spectrum.ieee.org/neuralink-blindsight {Quotes Ione Fine, Philip Troyk and Gislin Dagnelie; written before any Blindsight human study existed.}

[^smutny2026]: `paper` Smutny, Z., Hudec, M. and Kožuh, I. "Vision Restoration to People with Long-Term Blindness Using the Brain-Computer Interface Technology: A Sociotechnical Research Framework to Improve Usefulness for Users." *Patient Preference and Adherence*, 2026. {A perspective article drawing on earlier sight-restoration cases; it does not test Neuralink's device.}

[^debrief2025]: `news` Newton, C. "Neuralink Submits First Human Clinical Data for Peer Review, Marking Milestone in Brain-Computer Interface Research." *The Debrief*, 9 October 2025. {Relays a Bloomberg report of a disclosure by Barrow Neurological Institute's chief executive; the paper's findings were not released.}

[^nlseriesd]: `statement` Neuralink. "Neuralink Raises $280M Series D." Company blog post, 7 August 2023.

[^nlseriese]: `statement` Neuralink. "Neuralink raises $650 million Series E." Company blog post, 2 June 2025. {Gives the amount and investors but no valuation.}

[^zeff2025]: `news` Zeff, M. "Elon Musk's Neuralink closes a $650M Series E." *TechCrunch*, 2 June 2025. {The roughly $9 billion pre-money valuation is Semafor's reporting, relayed here; Neuralink did not disclose it.}

[^reuters2025]: `news` Reuters. "Neuralink plans 'high-volume' brain implant production by 2026, Musk says." 31 December 2025. {Reports a post by Musk on X; Neuralink did not respond to Reuters and gave no detail on volumes.}

[^nlmcmullen]: `statement` Neuralink. "Welcome, David McMullen!" Company blog post, 9 December 2025.

[^reuters2022]: `news` Levy, R. "Musk's Neuralink faces federal probe, employee backlash over animal tests." *Reuters*, 2022. {Based on internal documents and staff accounts; it reports that investigations were opened, which is not a finding that violations occurred.}

[^reuters2022]: `news` Levy, R. "Musk's Neuralink faces federal probe, employee backlash over animal tests." *Reuters*, 2022. {Based on internal documents and staff accounts; it reports that investigations were opened, which is not a finding that violations occurred.}

[^reuters2023]: `news` Levy, R. "U.S. investigating Elon Musk's Neuralink over hazardous pathogens." *Reuters*, February 2023. {Reports that an investigation was opened on an advocacy group's complaint; it is not a finding of a violation.}

[^cgtn2026]: `news` CGTN. "China leads the world in invasive BCI products." 29 March 2026. {Chinese state broadcaster; the approval date and device description match other reporting, but the world-first framing is its own.}